INTRODUCTION: Mucopolysaccharidosis type I (MPS I) results in a defective breakdown of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate, which leads to a progressive disease. Enzyme replacement therapy (ERT) results in clearance of these GAGs from a range of tissues and can significantly ameliorate several symptoms. The biochemical efficacy of ERT is generally assessed by the determination of the total urinary excretion of GAGs. However, this has limitations. We studied the concentrations of heparan sulfate and dermatan sulfate derived disaccharides (HS and DS, respectively) in the plasma and urine of seven patients and compared these levels with total urinary GAGs (uGAGs) levels. METHODS: Plasma and urine samples were collected at different time points relative to the weekly ERT for three non-consecutive weeks in seven MPS I patients who had been treated with ERT for at least 2.5 years. Heparan and dermatan sulfate in plasma and urine were enzymatically digested into disaccharides, and HS and DS levels were determined by HPLC-MS/MS analysis. uGAGs were measured by the DMB test. RESULTS: The levels of HS and DS were markedly decreased compared with the levels before the initiation of ERT. However, the concentrations of DS in plasma and of both HS and DS in urine remained significantly elevated in all studied patients, while in six patients the level of total uGAGs had normalized. The concentrations of plasma and urinary HS during the weekly ERT followed a U-shaped curve. However, the effect size is small. The concentrations of plasma and urinary DS and uGAGs appeared to be in a steady state. CONCLUSIONS: HS and DS are sensitive biomarkers for monitoring the biochemical treatment efficacy of ERT and remain elevated despite long-term treatment. This finding may be related to the labeled dose or antibody status of the patient. The timing of the sample collection is not relevant, at least at the current dose of 100 IU/kg/weekly.
INTRODUCTION:Mucopolysaccharidosis type I (MPS I) results in a defective breakdown of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate, which leads to a progressive disease. Enzyme replacement therapy (ERT) results in clearance of these GAGs from a range of tissues and can significantly ameliorate several symptoms. The biochemical efficacy of ERT is generally assessed by the determination of the total urinary excretion of GAGs. However, this has limitations. We studied the concentrations of heparan sulfate and dermatan sulfate derived disaccharides (HS and DS, respectively) in the plasma and urine of seven patients and compared these levels with total urinary GAGs (uGAGs) levels. METHODS: Plasma and urine samples were collected at different time points relative to the weekly ERT for three non-consecutive weeks in seven MPS Ipatients who had been treated with ERT for at least 2.5 years. Heparan and dermatan sulfate in plasma and urine were enzymatically digested into disaccharides, and HS and DS levels were determined by HPLC-MS/MS analysis. uGAGs were measured by the DMB test. RESULTS: The levels of HS and DS were markedly decreased compared with the levels before the initiation of ERT. However, the concentrations of DS in plasma and of both HS and DS in urine remained significantly elevated in all studied patients, while in six patients the level of total uGAGs had normalized. The concentrations of plasma and urinary HS during the weekly ERT followed a U-shaped curve. However, the effect size is small. The concentrations of plasma and urinary DS and uGAGs appeared to be in a steady state. CONCLUSIONS:HS and DS are sensitive biomarkers for monitoring the biochemical treatment efficacy of ERT and remain elevated despite long-term treatment. This finding may be related to the labeled dose or antibody status of the patient. The timing of the sample collection is not relevant, at least at the current dose of 100 IU/kg/weekly.
Authors: Muhammad Ameer Saif; Brian W Bigger; Karen E Brookes; Jean Mercer; Karen L Tylee; Heather J Church; Denise K Bonney; Simon Jones; J Ed Wraith; Robert F Wynn Journal: Haematologica Date: 2012-02-27 Impact factor: 9.941
Authors: H Church; K Tylee; A Cooper; M Thornley; J Mercer; E Wraith; T Carr; A O'Meara; R F Wynn Journal: Bone Marrow Transplant Date: 2007-01-15 Impact factor: 5.483
Authors: Monica Sifuentes; Robin Doroshow; Richard Hoft; Greg Mason; Irwin Walot; Michael Diament; Susan Okazaki; Kenneth Huff; Gerald F Cox; Stuart J Swiedler; Emil D Kakkis Journal: Mol Genet Metab Date: 2006-09-29 Impact factor: 4.797
Authors: Robert F Wynn; J Ed Wraith; Jean Mercer; Anne O'Meara; Karen Tylee; Margaret Thornley; Heather J Church; Brian W Bigger Journal: J Pediatr Date: 2009-04 Impact factor: 4.406
Authors: Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Lindsey Welling; Jan Pieter Marchal; Peter van Hasselt; Ans T van der Ploeg; Frits A Wijburg; Jaap Jan Boelens Journal: JIMD Rep Date: 2014-09-26
Authors: Eric P Schmidt; Guoyun Li; Lingyun Li; Li Fu; Yimu Yang; Katherine H Overdier; Ivor S Douglas; Robert J Linhardt Journal: J Biol Chem Date: 2014-02-07 Impact factor: 5.157
Authors: Sandra D K Kingma; Tom Wagemans; Lodewijk IJlst; Jurgen Seppen; Marion J J Gijbels; Frits A Wijburg; Naomi van Vlies Journal: JIMD Rep Date: 2015-04-09